Life Sciences

  • January 20, 2026

    Ex-Med Spa Workers Say Poaching Claims Can't Stay In Conn.

    Two former Connecticut medical spa workers have asked a judge to dismiss claims they lured clients and a colleague to a nearby competitor, saying their employment agreements select Delaware as the necessary forum and venue for any dispute.

  • January 20, 2026

    Johnson & Johnson Faces 2nd Talc Trial In Philadelphia

    Counsel for a woman who died of ovarian cancer told a Philadelphia jury Tuesday that her condition was caused by her decades-long use of asbestos-laced talc in Johnson & Johnson's flagship baby powder and that the company kept pushing the product in the market despite knowing about its health risks.

  • January 20, 2026

    Va. Lawmakers Eye Psilocybin Regulation Pending FDA Action

    Virginia lawmakers have introduced legislation directing state regulators to develop rules governing the prescription, possession and use of medical psilocybin, the active compound in psychoactive mushrooms, in the event that it receives approval from the U.S. Food and Drug Administration.

  • January 20, 2026

    CorMedix Investors Seek First OK Of Governance Reform Deal

    Investors in CorMedix Inc. have told a New Jersey federal judge that company directors have agreed to implement several corporate governance reforms to resolve a consolidated shareholder derivative lawsuit accusing the executives of making misleading statements about delays in the regulatory approval of the company's lead drug candidate.

  • January 20, 2026

    McCarter & English Knocks Down Biotech Malpractice Appeal

    A New Jersey appellate court on Tuesday upheld the dismissal of a biotech company's malpractice and related claims against McCarter & English LLP, finding the biotech company was required to bring those allegations during the firm's earlier suit to recover more than $837,000 in unpaid legal fees.

  • January 20, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court wrapped up last week with a mix of deal litigation, governance fights and disclosure battles, including a proposed settlement over a contested medical device sale, a merits dismissal tied to a $2 billion biotech exit and dueling lawsuits over Paramount Skydance's pursuit of Warner Bros. Discovery.

  • January 16, 2026

    Law360 Names Practice Groups Of The Year

    Law360 would like to congratulate the winners of its Practice Groups of the Year awards for 2025, which honor the attorney teams behind litigation wins and significant transaction work that resonated throughout the legal industry this past year.

  • January 16, 2026

    DOJ Reports Historic $6.8B False Claims Act Haul In 2025

    The U.S. Department of Justice secured more than $6.8 billion via settlements and judgments under the False Claims Act in the fiscal year that ended September 2025, the largest amount recovered in a single year in the history of the FCA, the DOJ said Friday.

  • January 16, 2026

    PBMs Seek Exit From Philly's Suit Over Opioid Crisis

    CVS Health Corp. and other pharmacy benefit managers asked a Pennsylvania federal judge to let them out of the city of Philadelphia's lawsuit claiming they contributed to the opioid epidemic in the city, arguing that the city waited too long to file its suit and lacked standing to sue the companies.

  • January 16, 2026

    SEC Fines Biopharma Co. Execs Over Hidden FDA Findings

    Former executives of Spero Therapeutics will pay over $187,000 to settle the U.S. Securities and Exchange Commission's claims they downplayed the likelihood that the U.S. Food and Drug Administration would reject the biopharmaceutical company's new drug application in 2022, the commission said on Friday.

  • January 16, 2026

    Lifecore Investors Ink $3.8M Deal In Accounting Controls Suit

    Biotech company Lifecore Biomedical Inc. has reached a $3.8 million deal with its investors to end their claims the company had weak controls over its financial reporting, impairing its ability to remain compliant with Nasdaq listing requirements and causing share declines.

  • January 16, 2026

    6th Circ. Revives Biomed Co. Investor's Suit Over Stock Sale

    The Sixth Circuit has ruled that a man who sold his stock in a biomedical research company just before being told the company planned to pursue private equity financing can bring his breach of contract and fiduciary duty claims, reversing a lower court's ruling granting summary judgment to the biomedical company.

  • January 16, 2026

    NuVasive Loses Appeal Over Ex-Exec's Ties To Competitor

    The Delaware Supreme Court on Friday affirmed the dismissal of NuVasive Inc.'s long-running lawsuit accusing a former top executive of breaching fiduciary duties and contractual obligations while planning to move to a rival spine-surgery company, ending nearly a decade of litigation over alleged conflicts and disloyal conduct.

  • January 16, 2026

    Acadia Investors Get Initial OK For $179M Settlement

    Acadia Healthcare Co. Inc. investors have received the first OK from a Tennessee federal judge for a $179 million settlement in a class action alleging the company misled them about the strength of its U.K. operations.

  • January 16, 2026

    Pomerantz To Lead Biohaven Investors' FDA Approval Suit

    Pomerantz LLP will lead a proposed class of investors accusing biopharmaceutical company Biohaven Ltd. of overstating the odds that two of its product candidates would receive regulatory approval, a Connecticut judge said Friday.

  • January 16, 2026

    Taxation With Representation: Stibbe, A&O Shearman, Latham

    In this week's Taxation With Representation, Keurig Dr Pepper Inc. plans to complete its deal to snap up coffee company JDE Peet's NV, Boston Scientific Corp. acquires medical device company Penumbra Inc., and fitness and wellness platform parent Playlist merges with fitness technology company EGYM.

  • January 16, 2026

    J&J Largely Loses Bid To Toss Former Atty's NJ Bias Suit

    A New Jersey federal judge largely shot down Johnson & Johnson's bid to scrap a former company data privacy attorney's racial and gender discrimination suit and rejected its bid to sanction her over the case.

  • January 16, 2026

    Supreme Court Takes On Hikma's 'Skinny Label' Patent Case

    The U.S. Supreme Court agreed Friday to hear Hikma Pharmaceuticals Inc.'s appeal of a decision reviving a patent case over its "skinny label" on a generic heart drug, after the Trump administration urged the court to take the case.

  • January 16, 2026

    Bioness $110M Sale Suit Heads to $8.9M Deal

    A Delaware Chancery Court class action challenging the $110 million sale of medical device maker Bioness Inc. to Bioventus Inc. is reaching a resolution through an $8.9 million proposed settlement, capping years of litigation over whether the deal was engineered to favor the company's controlling creditor at the expense of minority stockholders.

  • January 15, 2026

    SEC Says Healthcare Exec Misspent $10.6M In Investor Funds

    The U.S. Securities and Exchange Commission on Thursday accused a healthcare company CEO of misappropriating over $10 million from investors by falsely claiming the funds would be used to develop cancer screening and treatment technology when in fact they were spent on credit card debt, luxury vehicles and strip club visits.

  • January 15, 2026

    Ex-CEO Of COVID Vax Maker Accused Of Insider Trading

    New York Attorney General Letitia James on Thursday sued the former CEO of healthcare contractor Emergent BioSolutions Inc., alleging insider trading amid troubles manufacturing a COVID-19 vaccine, while signing a $900,000 settlement with the company over its approval of an executive trading plan.

  • January 15, 2026

    Trial 'No Longer Warranted' After Judge's Stelara Reversal

    The fate of insurer CareFirst's suit accusing Johnson & Johnson of using a merger and patent fraud to anticompetitively protect immunosuppressive drug Stelara from competition is in doubt after a Virginia federal judge reversed course and nixed key claims he had previously teed up for trial.

  • January 15, 2026

    Simpson Thacher Guides New Mountain's $1.2B Fund Close

    New Mountain Capital LLC, guided by Simpson Thacher & Bartlett LLP, has closed its second noncontrol private equity fund with $1.2 billion raised, aiming to use the funds to target companies in industries such as healthcare technology and life sciences, the alternative investment firm announced on Thursday.

  • January 15, 2026

    Chancery Tosses Vividion IP Suit Over $2B Bayer Deal

    The Delaware Chancery Court on Thursday dismissed a biotech investor's suit accusing the co-founder of Vividion Therapeutics Inc. and others of diverting valuable intellectual property ahead of the company's $2 billion sale to Bayer Corp., finding the alleged misconduct could not have affected the merger price or process under Delaware law.

  • January 15, 2026

    CVS Ducks Antitrust But Not Biz Interference Claim At 5th Circ.

    A Fifth Circuit panel has largely sided with CVS Pharmacy and its Caremark affiliate by preserving a district court's dismissal of federal antitrust claims over a Mississippi pharmacy's rejection from participating in the pharmacy benefit manager's network, although the judges did revive state law claims.

Expert Analysis

  • Series

    Coaching Cheerleading Makes Me A Better Lawyer

    Author Photo

    At first glance, cheerleading and litigation may seem like worlds apart, but both require precision, adaptability, leadership and the ability to stay composed under pressure — all of which have sharpened how I approach my work in the emotionally complex world of mass torts and personal injury, says Rashanda Bruce at Robins Kaplan.

  • 7 Ways To Fetch Patents In The World Of Working Animals

    Author Photo

    Though developers rarely file patents related to working animals, and animal training techniques are generally considered unpatentable, certain aspects of training and developing animals may be ripe for patent protection, say Matthew Avery at Baker Botts, Makenzi Galvan at Perkins Coie and Lute Yang at Orrick.

  • 9th Circ.'s Kickback Ruling Strengthens A Prosecutorial Tool

    Author Photo

    The Ninth Circuit's decision last month in U.S. v. Schena, interpreting the Eliminating Kickbacks in Recovery Act to prohibit kickback conduct between the principal and individuals who do not directly interact with patients, serves as a wake-up call to the booming clinical laboratory testing industry, say attorneys at Kendall Brill.

  • Series

    Law School's Missed Lessons: How To Make A Deal

    Author Photo

    Preparing lawyers for the nuances of a transactional practice is not a strong suit for most law schools, but, in practice, there are six principles that can help young M&A lawyers become seasoned, trusted deal advisers, says Chuck Morton at Venable.

  • From Clerkship To Law Firm: 5 Transition Tips For Associates

    Excerpt from Practical Guidance
    Author Photo

    Transitioning from a judicial clerkship to an associate position at a law firm may seem daunting, but by using knowledge gained while clerking, being mindful of key differences and taking advantage of professional development opportunities, these attorneys can flourish in private practice, say attorneys at Lowenstein Sandler.

  • 9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs

    Author Photo

    The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.

  • Associates Can Earn Credibility By Investing In Relationships

    Author Photo

    As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.

  • Puzzling Out When Similar Insurance Claims Are Related

    Author Photo

    A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.

  • A Shifting Trend In FDA Form 483 Disclosure Obligations

    Author Photo

    A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.

  • Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop

    Author Photo

    There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.

  • Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling

    Author Photo

    The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.

  • Breaking Down The Proposed Hemp Bill

    Author Photo

    A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.

  • Assessing Federal Securities Class Action Stats In '25 So Far

    Author Photo

    The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.

  • Series

    Quilting Makes Me A Better Lawyer

    Author Photo

    Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.

  • How Agentic AI Is Testing The Limits Of Patent Law

    Author Photo

    While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.